SEC Form 4 · accession 0001567619-18-001756
IDEXX LABORATORIES INC /DE · IDXX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jacqueline Studer
Officer — CVP, Gen. Counsel & Secretary
Period of report
Aug 21, 2018
Accepted (ET)
Aug 23, 2018 · 6:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000874716
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 21, 2018 | M | 9,400 | $67.85 | A | 17,034 | D | |
| Common Stock | Aug 21, 2018 | M | 2,219 | $141.60 | A | 19,253 | D | |
| Common StockF1 | Aug 21, 2018 | S | 5,549 | $243.359 | D | 13,704 | D | |
| Common StockF2 | Aug 21, 2018 | S | 2,806 | $244.1514 | D | 10,898 | D | |
| Common StockF3 | Aug 21, 2018 | S | 3,264 | $245.0634 | D | 7,634 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right-to-buy)F6,F4 | $67.85 | Aug 21, 2018 | M | 9,400 | D | — | Feb 13, 2026 | Common Stock | 9,400 | 12,627 | D |
| Non-Qualified Stock Option (right-to-buy)F6,F5 | $141.60 | Aug 21, 2018 | S | 2,219 | D | — | Feb 13, 2027 | Common Stock | 2,219 | 8,167 | D |
Explanation of responses
- F1Represents the weighted average sales price of the shares sold ranging from a low of $243.00 to a high of $243.69 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F2Represents the weighted average sales price of the shares sold ranging from a low of $244.00 to a high of $244.56 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F3Represents the weighted average sales price of the shares sold ranging from a low of $245.00 to a high of $245.13 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F4Grant of option to buy 22,027 shares of IDEXX Laboratories, Inc. common stock that vests and is exercisable in five equal annual installments beginning on February 14, 2017.
- F5Grant of option to buy 10,386 shares of IDEXX Laboratories, Inc. common stock that vests and is exercisable in five equal annual installments beginning on February 14, 2018.
- F6Not applicable.